Related Experiment Video

Updated: Sep 3, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

The effect of low-dose simvastatin in children with familial hypercholesterolaemia: a 1-year observation

Albert Dirisamer1, Nilouparak Hachemian, Robert Alexander Bucek

  • 1Department of Paediatrics, University of Vienna, Währinger Gürtel 18-20, 1090, Austria.

European Journal of Pediatrics
|May 21, 2003
PubMed

Insights

Low-dose simvastatin effectively lowers cholesterol in children and adolescents with familial hypercholesterolaemia (FH). This study found simvastatin to be a safe treatment option for managing FH in pediatric patients.

Area of Science:

  • Pediatrics
  • Cardiology
  • Pharmacology

Background:

  • Familial hypercholesterolaemia (FH) is a genetic lipid metabolism disorder.
  • FH significantly increases the risk of early-onset cardiovascular disease due to atherosclerotic lesions.
  • Early diagnosis and treatment are crucial for preventing cardiovascular complications in FH patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of low-dose simvastatin in children and adolescents diagnosed with FH.
  • To assess the impact of simvastatin on lipid profiles, including LDL-C, total cholesterol, HDL-C, and triglycerides.
  • To monitor for any adverse effects associated with simvastatin treatment in this pediatric population.

Main Methods:

  • A 1-year study involving 20 children and adolescents (aged 10-17) with FH.
  • Participants were divided into groups receiving initial simvastatin doses of 5 mg/day or 10 mg/day based on baseline LDL-C levels.
  • Dosages could be increased up to 20 mg/day if LDL-C targets (<170 mg/dl) were not met; regular monitoring of weight, height, lipids, and safety parameters was conducted.

Main Results:

  • Simvastatin treatment led to significant reductions in LDL-C and total cholesterol across all dosage groups (5 mg, 10 mg, 20 mg).
  • LDL-C decreased by 25-36%, and total cholesterol by 19-29% depending on the dosage.
  • HDL-C and triglyceride levels also showed favorable changes, with triglycerides decreasing by 12.6-21%.

Conclusions:

  • Low-dose simvastatin demonstrates effectiveness in managing lipid levels in pediatric patients with FH.
  • The study indicates that simvastatin is a safe therapeutic option for children and adolescents with familial hypercholesterolaemia.
  • Observed side effects were minor and transient, supporting the favorable safety profile of simvastatin in this age group.
Abstract

More Related Videos

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...